Efficacy Of Ghaza Husne Afza In Comparison With Triple Compound Cream In Epidermal Melasma (Kalaf)- A Split Face Controlled Clinical Trial.
试验速览
- 阶段
- 2/3 期
- 状态
- 尚未招募
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- 1.Decrease in area of involvement of mMASI score
研究概览
简要总结
Need of the study:- Hyperpigmented lesions on the face have always been a distressing symptom to the patient. In the present era, people have been showing a growing interest in physical appearance. Hence, the number of patients seeking dermatologist care for facial hypermelanosis has been increasing day by day1.
Melasma is a common acquired disorder characterized by symmetric, hyperpigmented patches with an irregular outline, occurring most commonly on the face2.
In Unani books it is termed “kalaf” or “Jhayian” [IUMT-5.13.13] and has been described by ancient Unani physicians as the accumulation of blood under the skin due to the rupture of minute capillaries, this accumulated blood is the reason for hyperpigmentation3.
The pathogenesis is not completely understood. Biologically active melanocytes, genetic and hormonal influences, and ultraviolet light exposure are known to be important. Specific precipitants, particularly oral contraceptives and estrogen replacement therapy, have been implicated in exacerbating the condition4. Globally, the prevalence of melasma is variable. As a multifactorial disorder, its prevalence has been observed from 1% in the general population to 9-50% in high-risk populations. Although it presents in 0.25-4% of dermatology clinic patients in Southeast Asia, a prevalence as high as 40% has been reported in the population7. Although melasma does not cause any major health-related complications but severely affects the social life as well as the emotional well-being of the patients therefore, negatively affecting the quality of life of patients. There is no universally accepted and effective therapeutic agent for the cure of melasma. Conventional treatments include topical and oral medications, resurfacing techniques like chemical peeling, light, and laser treatments, etc. Most of these treatments may also lead to skin irritation and further worsening of cutaneous pigmentation or even scarring. A triple combination cream containing hydroquinone, tretinoin, and steroids is currently the only approved treatment for melasma. Unani drugs are reported to be very effective in the management of various dermatological diseases: many herbal drugs have been mentioned to be beneficial in the treatment of melasma. However, it is necessary to validate these drugs based on scientific parameters through clinical studies8.
Hence, the present study was planned to clinically evaluate the efficacy of topical unani formulation Ghaza Husne Afza in the management of Epidermal Melasma (Kalaf).
Review of Literature:
The term MELASMA (Kalaf) comes from the Greek word “melas”, which means black. In 1923, Dr. W.G Spencer proposed a theory for the origin of melanin. In 1929, Dr. Gupta used the term “Melanoderma” to describe a butterfly distribution of facial pigmentation with varying intensity9.
Melasma is the most common cause of facial melanosis and is manifested by hyperpigmented macules on the face that become more pronounced after sun exposure5. Light to dark brown or brown-gray patches with irregular borders appear primarily on the face. The areas of hypermelanosis are distributed symmetrically in three classic patterns: [1] centrofacial(most common), involving the forehead, cheeks, nose, upper lip (sparing the philtrum and nasolabial folds), chin; [2] malar, affecting the cheeks and nose; and [3] mandibular, along the jawline2.The etiology is multifactorial. Ultraviolet radiation is thought to be the most significant trigger. It activates inducible nitric oxide and reactive oxygen species (ROS), thereby promoting melanogenesis. Genetic predisposition is thought to be an important factor in the development of melasma. Increased prevalence of melasma in pregnancy, OCP use, and other hormonal therapies suggest a possible hormonal etiology as well. Besides, melasma has been found to coexist with lentigines, nevi, and thyroid disease. Histology shows increased melanin deposition in the epidermis (basal and suprabasal keratinocytes) and/or dermis (superficial and mid, maybe perivascular)6.
Melasma has classically been subdivided into four types: -2
1. Epidermal
2. Dermal
3. Mixed
4. Indeterminate
In theory, lesions with increased epidermal melanin are accentuated and those with increased dermal melanin becomes less obvious (i.e. blend with uninvolved skin) with Wood’s lamp examination2. Treatment options include photoprotection and topical medications [hydroquinone(HQ), corticosteroids, retinoids, 4-n-butyl resorcinol, tranexamic acid, niacinamide, ascorbic acid, azelaic acid, kojic acid, arbutin, N-acetyl-4-S-cysteaminylphenol, mequinol, alpha-tocopheryl ferulate, licorice, flavonoids, beta-carotene, rucinol, dioic acid, methimazole, silymarin, etc.] Systemic medications include tranexamic acid, glutathione, L-cysteine peptide, polypodium leucotomos extract, oral antioxidants (vitamins A, C, and E), pycnogenol/procyanidin, melatonin, herbal extracts (Rhus vernciflua), etc. Procedural therapies include chemical peeling (glycolic, mandelic, trichloroacetic acid, tretinoin, obagi blue peel, combination peels, etc.), micro-needling, lasers (low-frequency Q-switched Nd: YAG laser), nonpolar radiofrequency, and a newer technique (laser toning or laser facial). Other physical modalities like microneedling are also used for recalcitrant melasma6.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 18.00 Year(s) 至 50.00 Year(s)(—)
- 性别
- Female
入选标准
- •1.Clinically diagnosed cases of epidermal malar melasma.
- •2.Female patients aged between 18-50 years.
- •3.Fitzpatricks Skin phototype III, IV and V
- •4.Patients who will give consent and are able to do follow-up.
排除标准
- •1.Pregnant and lactating women.
- •2.Patients who previously applied topical treatment like hydroquinone, azelaic acid, glycolic acid, corticosteroid, or any depigmenting agents or any cosmetic procedure 1 month before the study.
- •3.Patients having cutaneous infections like herpes, facial warts, and active dermatoses.
结局指标
主要结局
1.Decrease in area of involvement of mMASI score
时间窗: 0th Day ,15th Day,30th Day,45th Day,60th Day
次要结局
- 1.Improvement in DLQI score(2.Improvement in photographs of the lesions)
研究者
Dr Diksha S Padsale
National Institute Of Unani Medicine
